Tocqueville Asset Management’s Viking Therapeutics VKTX Stock Holding History

Tocqueville Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,230	Closed	-$814K	–	557
2024 Q4	$814K	Buy	+20,230	New	+$1.15M	0.01%	377
2019 Q4	–	Sell	-25,275	Closed	-$174K	–	771
2019 Q3	$174K	Sell	25,275 -9,475	-27%	-$70.4K	﹤0.01%	729
2019 Q2	$288K	Sell	34,750 -23,125	-40%	-$198K	﹤0.01%	689
2019 Q1	$575K	Buy	57,875 +16,300	+39%	+$136K	0.01%	563
2018 Q4	$318K	Sell	41,575 -2,825	-6%	-$33.8K	﹤0.01%	622
2018 Q3	$773K	Buy	+44,400	New	+$528K	0.01%	540

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tocqueville Asset Management's VKTX Position: Q1 2025 in Review

Tocqueville Asset Management sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 20,230 shares — an estimated $814K sold.

Tocqueville Asset Management first reported a position in VKTX in Q3 2018 and held it in 6 quarters. The position peaked at $814K in Q4 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

Tocqueville Asset Management reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
Tocqueville Asset Management sold 20,230 Viking Therapeutics shares in Q1 2025, an estimated $814K.
Tocqueville Asset Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 6 quarters.
Tocqueville Asset Management's Viking Therapeutics position peaked at $814K in Q4 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Tocqueville Asset Management's 13F filing for Q1 2025, filed 13 May 2025.